0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      671. Introduction of simultaneous Clostridioides difficile Antigen and Toxin A and B detection for diagnosis of C. difficile related diarrhea at Michael E. DeBakey VA Medical Center

      abstract

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Nucleic acid amplification test (NAAT) for diagnosis of Clostridioides difficile infection (CDI) is highly sensitive but is unable to distinguish colonization from infection. Antigen/toxin testing on the other hand may have lower sensitivity, especially early in infection with associated delay in diagnosis.

          Methods

          We conducted a retrospective study at Michael E. DeBakey VA Medical Center prior and post the introduction of simultaneous C.difficile GDH Antigen and Toxin A/B (GDH/Tox) detection.

          Results

          In the pre-intervention period 83 patients underwent NAAT, 16 patients had a positive test result (19.3%). In the post-intervention 120 patients were tested; 99 (82.5%) were negative for both GDH Antigen and toxin A/B (GDH-/tox-), 16 (13.3%) tested positive for the GDH Antigen but negative for Toxin A/B (GDH+/tox-) and 5 (4.2%) tested positive for both Antigen and Toxin (GDH+/tox+). Two patients (1.7%) who initially tested GDH+/tox- were subsequently retested due to persistent symptoms or evidence of colitis and were noted to have GDH+/tox+ result.

          The rate of positivity of C.difficile testing in our institution decreased form 19.3% to 4.2% (p< .001) post introduction of the GDH/toxin A/B detection. The treatment rate of patients who had the test performed decreased from 18.1% to 9.2% (p=.062).

          30-day readmission rate for any reason in the group that tested positive for CDI in the pre-intervention group was 18.5% (3 patients), with 30-day all-cause mortality 6.25% (1 patient). In the GDH+/tox+ and GDH+/tox- groups in the post-intervention period, the 30-day readmission rate for any cause was 9.5% (2 patients), and 30-day all-cause mortality was 6.25% (1 patient).

          CDI testing results before and after the intervention.

          Conclusion

          Distinguishing asymptomatic carriage or colonization from CDI remains an important goal. Implementing GDH Antigen and toxin A/B C.difficile testing can help reduce the risk of inappropriate treatment of colonization and possibly reduce the risk for development of antibacterial resistant C.difficile strains, however in our case it initially missed 2 cases of CDI that fortunately was not associated with negative outcome. With use of the GDH/tox test repeat testing and/or treatment might be considered on case-by-case basis depending on persistence of symptoms or high suspicion of infection.

          Disclosures

          All Authors: No reported disclosures

          Related collections

          Author and article information

          Contributors
          Journal
          Open Forum Infect Dis
          Open Forum Infect Dis
          ofid
          Open Forum Infectious Diseases
          Oxford University Press (US )
          2328-8957
          December 2023
          27 November 2023
          27 November 2023
          : 10
          : Suppl 2 , IDWeek 2023 Abstracts
          : ofad500.733
          Affiliations
          Baylor College of Medicine , Houston, Texas
          Baylor College of Medicine, Michael E. DeBakey VA Medical Center , Housotn, Texas
          Baylor Collage of Medicine , Houston, Texas
          Baylor College of Medicine, Michael E. DeBakey VA Medical Center , Housotn, Texas
          Baylor College of Medicine, Michael E. DeBakey VA Medical Center , Housotn, Texas
          Michael E. DeBakey VAMC and Baylor College of Medicine , Houston, Texas
          Author notes

          Session: 54. HAI: C. difficile

          Thursday, October 12, 2023: 12:15 PM

          Article
          ofad500.733
          10.1093/ofid/ofad500.733
          10679194
          ccb81fd0-add5-4675-8ab6-5af659a30eb3
          © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

          History
          Categories
          Abstract
          AcademicSubjects/MED00290

          Comments

          Comment on this article